NCT04658004

NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Clinical Trial for the Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.

Detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory NKG2D ligand positive acute myeloid leukemia. The selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. Primary objective is to explore the safety,main consideration is dose-related safety.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	NKG2D CAR T-cells	Each subject receive NKG2D CAR T-cells by intravenous infusion

Timeline

• Start date: 2021-01-15
• Primary completion: 2024-01-15
• Completion: 2027-01-15
• First posted: 2020-12-08
• Last updated: 2020-12-08

Locations

1 site across 1 country: China